Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of Universe Pharmaceuticals INC from 30 Sep 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Universe Pharmaceuticals INC quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD history and change rate from 30 Sep 2019 to 30 Sep 2025.
  • Universe Pharmaceuticals INC Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending 30 Sep 2025 was $33,592,025,000.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Change (%)

Universe Pharmaceuticals INC Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $33,592,025,000* +$4,094,332,000 30 Sep 2025 20-F 29 Jan 2026 2025 FY
Q3 2024 $29,497,693,000* +$24,212,446,000 30 Sep 2024 20-F 29 Jan 2026 2025 FY
Q1 2024 $8,861,590 -$4,092,926 -32% 31 Mar 2024 6-K 20 Sep 2024 2024 Q2
Q3 2023 $5,285,247,000 -$426,211,000 -7.5% 30 Sep 2023 20-F 29 Jan 2026 2025 FY
Q1 2023 $12,954,516 -$1,281,784 -9% 31 Mar 2023 6-K 20 Sep 2024 2024 Q2
Q3 2022 $5,711,458,000 +$5,703,380,092 +70605% 30 Sep 2022 20-F 29 Jan 2026 2025 FY
Q1 2022 $14,236,300 -$21,762,829 -60% 31 Mar 2022 6-K 31 Aug 2023 2023 Q2
Q3 2021 $8,077,908 -$1,980,294 -20% 30 Sep 2021 20-F 29 Apr 2025 2024 FY
Q1 2021 $35,999,129 31 Mar 2021 6-K 16 Aug 2022
Q3 2020 $10,058,202 +$6,880,881 +217% 30 Sep 2020 20-F 30 Jan 2024 2023 FY
Q3 2019 $3,177,321 30 Sep 2019 20-F 10 Feb 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.